We are live on ! Find out more
SM

Sabby Management Portfolio holdings

AUM $111M
1-Year Est. Return 74.4%
This Fund
S&P 500
This Quarter Est. Return
-2.86%
1 Year Est. Return
-74.4%
3 Year Est. Return
-95.55%
5 Year Est. Return
-99.44%
10 Year Est. Return
-99.5%
AUM
$1.1B
AUM Growth
-$432M
Cap. Flow
+$36.5M
Cap. Flow %
3.32%
Top 10 Hldgs %
65.53%
Holding
227
New
63
Increased
36
Reduced
51
Closed
66

Top Buys

Rank Stock Value
1
ODT
Odonate Therapeutics, Inc. Common Stock
ODT
+$19.5M
2
ONCE
Spark Therapeutics, Inc. Common Stock
ONCE
+$7.96M
3
MNKD icon
MannKind Corp
MNKD
+$4.94M
4
ESPR
Esperion Therapeutics
ESPR
+$3.17M
5
BNBX
BNB PLUS CORP
BNBX
+$2.81M

Top Sells

Rank Stock Value
1
GWPH
GW Pharmaceuticals Plc American Depositary Shares
GWPH
+$3.35M
2
BMY icon
Bristol-Myers Squibb
BMY
+$3.2M
3
SIOX
Sio Gene Therapies Inc. Common Stock
SIOX
+$2.96M
4
SGEN
Seagen Inc. Common Stock
SGEN
+$2.32M
5
HURA
TuHURA Biosciences
HURA
+$1.78M

Sector Composition

Rank Sector Weight
1 Miscellaneous 86.88%
2 Healthcare 12.71%
3 Financials 0.19%
4 Technology 0.09%
5 Industrials 0.07%
Name Market Value Portfolio Weight Shares or Principal Change
in Stake 		Capital Flow
OREX
226
DELISTED
Orexigen Therapeutics, Inc.
OREX
– –
-19,700
Closed -$42K
OREX
227
PUT
DELISTED
Orexigen Therapeutics, Inc.
OREX
– –
-197
Closed -$42K
6 7 8 9
10

Similar funds

IWA
Independent Wealth Advisors Cary, North Carolina $111M AUM
BFA
Ballast Financial Advisors West Chester, Pennsylvania $110M AUM
WPWM
Western Pacific Wealth Management Lake Forest, Illinois $111M AUM 26.64% 1-Year Est. Return
BCM
Beryl Capital Management Redondo Beach, California $111M AUM 205.39% 1-Year Est. Return
ZS
Zenith Solutions Philadelphia, Pennsylvania $110M AUM
KC
Karras Company Roy, Utah $110M AUM
FI
FinArc Investments Norwood, Massachusetts $110M AUM
CIM
Catalyst Investment Management Windham, New Hampshire $110M AUM

Sabby Management's Q4 2017 Portfolio in Review

As of Q4 2017, Sabby Management held 227 positions worth $1.1B, down 28% from $1.53B the previous quarter. Its ten largest holdings account for 66% of the portfolio.

Sabby Management deployed $36.5M of net new capital in Q4 2017, opening 63 new positions and adding to 36 existing holdings. Its largest new stake was Odonate Therapeutics, Inc. Common Stock: 825,451 shares worth $20.6M.

By sector, the portfolio is most concentrated in Miscellaneous at 87% of assets, down from 92% a quarter earlier, followed by Healthcare and Financials.

On the sell side, the largest reduction was Bristol-Myers Squibb, an estimated $3.2M trimmed.

  • Sabby Management's largest Q4 2017 buy was Odonate Therapeutics, Inc. Common Stock: 825,451 shares worth $20.6M.
  • Sabby Management added most to Esperion Therapeutics in Q4 2017, an estimated $3.17M increase.
  • Sabby Management's biggest Q4 2017 reduction was Bristol-Myers Squibb, cutting an estimated $3.2M.
  • Sabby Management fully exited GW Pharmaceuticals Plc American Depositary Shares in Q4 2017, selling an estimated $3.35M.
  • Sabby Management's ten largest holdings make up 66% of its $1.1B portfolio in Q4 2017.
  • Sabby Management opened 63 new positions and closed 66 in Q4 2017.
  • Sabby Management's portfolio value fell 28% quarter-over-quarter to $1.1B.

Based on Sabby Management's 13F filing for Q4 2017, filed 14 Feb 2018.